Alto Neuroscience Inc (ANRO)

Currency in USD
14.75
+0.95(+6.88%)
Closed·
14.95+0.20(+1.36%)
·
ANRO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.6014.92
52 wk Range
1.6015.18
Key Statistics
Prev. Close
13.8
Open
13.63
Day's Range
13.6-14.92
52 wk Range
1.6-15.18
Volume
439.06K
Average Volume (3m)
1.55M
1-Year Change
205.31%
Book Value / Share
4.12
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ANRO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.57
Upside
+100.48%
Members' Sentiments
Bearish
Bullish
ProTips
Stock generally trades with high price volatility

Alto Neuroscience Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Alto Neuroscience Inc Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Compare ANRO to Peers and Sector

Metrics to compare
ANRO
Peers
Sector
Relationship
P/E Ratio
−6.0x−1.6x−0.6x
PEG Ratio
−0.22−0.020.00
Price/Book
3.3x1.3x2.6x
Price / LTM Sales
-2.3x3.3x
Upside (Analyst Target)
81.2%282.1%43.2%
Fair Value Upside
Unlock1.6%5.6%Unlock

Analyst Ratings

8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 29.57
(+100.48% Upside)

Earnings

Latest Release
Nov 12, 2025
EPS / Forecast
-0.52 / -0.64
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ANRO Income Statement

People Also Watch

8.28
CRML
-0.30%
20.870
GLTO
-8.67%
7.340
GSIT
-0.81%
0.5350
BENF
+5.44%
2.550
GWH
-0.78%

FAQ

What Is the Alto Neuroscience (ANRO) Premarket Price Today?

The Alto Neuroscience (ANRO) premarket price is 13.01. Premarket price change units: -0.79. Premarket percentage change: -5.72%. Premarket volume: 28,530.00. Current date: 19 Nov 2025. Previous close: 13.80

What Stock Exchange Does Alto Neuroscience Trade On?

Alto Neuroscience is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Alto Neuroscience?

The stock symbol for Alto Neuroscience is "ANRO."

What Is the Alto Neuroscience (ANRO) Afterhours Price Today? (Afterhours variable test: 14.95) Current Date: 19 Nov 2025

After hours price: 14.95. After hours price change (units): 0.20. Price change percentage: 1.36%

What Is the Alto Neuroscience Market Cap?

As of today, Alto Neuroscience market cap is 373.66M.

What Is Alto Neuroscience's Earnings Per Share (TTM)?

The Alto Neuroscience EPS (TTM) is -2.31.

When Is the Next Alto Neuroscience Earnings Date?

Alto Neuroscience will release its next earnings report on 11 Nov 2025.

From a Technical Analysis Perspective, Is ANRO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alto Neuroscience Stock Split?

Alto Neuroscience has split 0 times.

How Many Employees Does Alto Neuroscience Have?

Alto Neuroscience has 76 employees.

What is the current trading status of Alto Neuroscience (ANRO)?

As of 19 Nov 2025, Alto Neuroscience (ANRO) is trading at a price of 14.75, with a previous close of 13.80. The stock has fluctuated within a day range of 13.60 to 14.92, while its 52-week range spans from 1.60 to 15.18.

What Is Alto Neuroscience (ANRO) Price Target According to Analysts?

The average 12-month price target for Alto Neuroscience is USD29.57143, with a high estimate of USD50 and a low estimate of USD13. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +100.48% Upside potential.

What Is the ANRO Premarket Price?

ANRO's last pre-market stock price is 13.01. The pre-market share volume is 28,530.00, and the stock has decreased by -0.79, or -5.72%.

What Is the ANRO After Hours Price?

ANRO's last after hours stock price is 14.95, the stock has decreased by 0.20, or 1.36%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.